Original articleAn Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration
Section snippets
Methods
PrONTO is a two-year, open-label, prospective, single-center clinical study designed to investigate the efficacy, durability, and safety of a variable dosing regimen with intravitreal ranibizumab in patients with neovascular AMD. The PrONTO Study is an investigator sponsored trial supported by Genentech, Inc, and performed with the approval of the Food and Drug Administration. Before the initiation of the study, additional approval for the PrONTO study was obtained from the Institutional Review
Baseline Characteristics
Between August 2004 and April 2005, 69 patients were screened for the study and 40 patients were enrolled. Twenty-nine patients were excluded from the study for the following reasons: OCT central retinal thickness less than 300 μm (nine patients), declined participation in the study after screening because of the rigorous follow-up schedule (seven patients), visual acuity either better than 20/40 or worse than 20/400 (four patients), inability to obtain reproducible OCT central retinal
Discussion
In the PrONTO study, intravitreal injections of ranibizumab were shown to rapidly reduce the amount of macular fluid in eyes of patients with neovascular AMD while improving visual acuity. Within one day, both the mean and median OCT central retinal thickness measurements decreased significantly, and by day 14, both the mean and median visual acuity measurements had improved. Continued improvements were evident within the first 3 months after the three scheduled ranibizumab injections and these
Anne E. Fung, MD, graduated with honors in Chinese Studies and Economics from Wellesley College in 1993 and received her MD from Cornell University Medical College in 1999. After completing residency at Stanford University, she pursued a research fellowship at the Smith Kettlewell Eye Research Institute. In 2005, she completed a Medical Retina fellowship at the Bascom Palmer Eye Institute and returned to San Francisco to join her father at Pacific Eye Associates/California Pacific Medical
References (8)
- et al.
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen
J Mol Biol
(1999) - et al.
VEGF Inhibition Study in Ocular Neovascularization Clinical Trial GroupPegaptanib for neovascular age-related macular degeneration
N Engl J Med
(2004) - et al.
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Ranibizumab vs verteporfin for neovascular age-related macular degeneration
N Engl J Med
(2006)
Cited by (906)
Towards a population pharmacokinetic/pharmacodynamic model of anti-VEGF therapy in patients with age-related macular degeneration
2023, European Journal of Pharmaceutics and BiopharmaceuticsAssociations between Serial Intravitreal Injections and Dry Eye
2023, OphthalmologyInjection Frequency and Differences in Visual Outcomes based on Diagnosis Year in Neovascular Age-related Macular Degeneration
2024, Journal of Korean Ophthalmological Society
Anne E. Fung, MD, graduated with honors in Chinese Studies and Economics from Wellesley College in 1993 and received her MD from Cornell University Medical College in 1999. After completing residency at Stanford University, she pursued a research fellowship at the Smith Kettlewell Eye Research Institute. In 2005, she completed a Medical Retina fellowship at the Bascom Palmer Eye Institute and returned to San Francisco to join her father at Pacific Eye Associates/California Pacific Medical Center where she continues clinical research in age-related macular degeneration.
Geeta A. Lalwani, MD, is currently a surgical retina fellow at the Bascom Palmer Eye Institute in Miami, Florida. She received an AB from Smith College, and an MD from the MCP-Hahnemann School of Medicine, where she was elected into the Alpha Omega Alpha honor society. She will complete her fellowship in July 2007.
See accompanying Editorial on page 679.